Baxter International Inc. is an American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. Wikipedia.
Baxter International and Baxter Healthcare SA | Date: 2017-02-01
A dialysis system having multi-heater power coordination is described. In one embodiment, the system (10a, 10b) comprises: a first fluid heater; a second fluid heater; and a logic implementer (32, 50) configured to synchronize the duty cycles of the first and second heaters so that the first and second heaters are powered simultaneously as little as possible if a collective duty cycle of the first and second heaters is greater than one hundred percent. In another embodiment, the dialysis system (10a, 10b) comprises: a first fluid heater; a second fluid heater; a supplemental power source (14); and a logic implementer (32, 50) configured to use the supplemental power source such that when the first and second heaters are powered simultaneously, a collective current draw does not exceed a maximum allowable current draw of a branch power source (12) powering the system.
Kewpie Kabushiki Kaisha also Trading As Kewpie Corporation and Baxter International | Date: 2017-02-08
An injection bag is formed of a laminate film, and includes an intermediate layer that includes a mixture of 60 to 90 mass% of a crystalline polyamide resin and 10 to 40 mass% of a noncrystalline polyamide resin. The crystalline polyamide resin has a combined content of a monomer and a low-molecular-weight polymer of 0.8 mass% or less. The noncrystalline polyamide resin includes a semi-aromatic polyamide.
Baxter International, Baxter Healthcare SA and Dyax | Date: 2017-01-18
The present application relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function.
Baxter International and Baxter Healthcare SA | Date: 2017-03-09
A renal failure blood therapy system includes a renal failure blood therapy machine, concentration levels for each of a plurality of solutes removed from a patients blood at each of the multiple times, a display device configured to display for selection at least one removed blood solute from the plurality of removed blood solutes, and a device programmed to (i) estimate at least one renal failure blood therapy patient parameter using the determined concentration levels for the at least one selected removed blood solute, (ii) determine a plurality of acceptable renal failure blood therapy treatments that meet a predetermined removed blood solute clearance for the at least one selected removed blood solute using the at least one renal failure blood therapy patient parameter, and (iii) enable selection of at least one of the plurality of acceptable renal failure blood therapy treatments for operation at the renal failure blood therapy machine.
Baxter International and Baxter Healthcare SA | Date: 2017-02-06
A peritoneal dialysis system includes: a drain container; a drain line placed in fluid communication with the drain container and configured to be placed in fluid communication with a patients peritoneal cavity; a vacuum source configured to apply a pneumatic force to cause used dialysis fluid to flow through the drain line from the patients peritoneal cavity to the drain container; a weight sensor configured to output a weight of used dialysis fluid delivered to the drain container from the patients peritoneal cavity; and a controller configured to: (i) determine an actual flow rate of used dialysis fluid removed from the patients peritoneal cavity based on the output from the weight sensor; (ii) compare the actual flow rate to a desired flow rate; and (iii) adjust the pneumatic force applied by the vacuum source to attempt to match the actual flow rate to the optimal flow rate.
Baxter International and Baxter Healthcare SA | Date: 2017-05-24
This application discloses devices, articles, and methods useful for producing lyophilized cakes of solutes. The devices and articles provide for a method of freezing liquid solutions of the solute by the top and the bottom of the solution simultaneously and at approximately the same rate. The as frozen solution can then provide a lyophilized cake of the solutes with large and uniform pores.
Baxter International and Baxter Healthcare SA | Date: 2017-06-07
A method for detecting an access disconnect, the method comprising:placing an acoustic sensor upstream of a venous access site;detecting a first heart beat of a patient;determining a first baseline signal from the first heart beat;sensing a second heart beat of the patient;determining a second baseline signal from the second heart beat;comparing the second baseline signal to the first baseline signal; andsending an alert if the step of comparing indicates that the access disconnect or a leak has occurred.
Baxter International, Baxter Healthcare Sa and Northwestern University | Date: 2017-03-03
The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.
Baxter International and Baxter Healthcare SA | Date: 2017-05-10
The invention relates to a hemodialysis system comprising a blood component portion including a blood pump; a blood cassette (150) operatively connected to the blood pump such that the blood pump can pump blood through the blood cassette (150) when the blood cassette (150) is in fluid communication with a blood source; a dialyzer fluidly connected to the blood cassette (150); a dialysate component portion separate from the blood component portion, the dialysate component portion including a dialysate pump; and a dialysate cassette (10e) separate from the blood cassette (150), the dialysate cassette (10e) operatively connected to the dialysate pump such that the dialysate pump can pump dialysate through the dialysate cassette (10e) when the dialysate cassette (10e) is in fluid communication with the dialysate source, the dialysate cassette being fluidly connected to the dialyzer.
Baxter International and Baxter Healthcare S.A. | Date: 2017-09-20
A handheld personal communication apparatus (30a, 30b, 30c, 60, 90) for dialysis is described. The device comprises: a reader (38, 42, 92, 94) configured to perform at least one of (i) read a marking (18) displayed on a dialysis fluid container (16) to acquire data concerning at least one of a dialysis fluid type or a dialysis fluid volume from the marking, or (ii) receive a patient weight signal from a weight scale (20); a processor (44, 98) configured use the at least one of the dialysis fluid type, the dialysis fluid volume, or the patient weight signal to determine a dialysis dwell time for at least one cycle of a dialysis therapy for a patient, the dialysis dwell time corresponding to a time to achieve at least one of (a) a specified ultrafiltrate level for the at least one cycle, (b) a urea removal level for the at least one cycle, or (c) a creatinine removal level for the at least one cycle; and an output interface (48, 62, 102) configured to provide an indication to the patient of a completion of the dialysis dwell time. A method of providing a completion of the dialysis dwell time using a handheld personal communication apparatus (30a, 30b, 30c, 60, 90) is also described.